Mueller BU - Search Results

1

C/EBPalpha and the pathophysiology of acute myeloid leukemia.

Mueller BU, Pabst T. Mueller BU, et al. Curr Opin Hematol. 2006 Jan;13(1):7-14. doi: 10.1097/01.moh.0000190110.08156.96. Curr Opin Hematol. 2006. PMID: 16319681 Review.

2

Disease evolution and outcomes in familial AML with germline CEBPA mutations.

Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, Döhner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J. Tawana K, et al. Blood. 2015 Sep 3;126(10):1214-23. doi: 10.1182/blood-2015-05-647172. Epub 2015 Jul 10. Blood. 2015. PMID: 26162409

3

Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia.

Berger MD, Heini AD, Seipel K, Mueller B, Angelillo-Scherrer A, Pabst T. Berger MD, et al. Hematol Oncol. 2017 Dec;35(4):789-796. doi: 10.1002/hon.2307. Epub 2016 Jun 15. Hematol Oncol. 2017. PMID: 27301773

4

Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemia.

Alva LC, Bacher U, Seipel K, Mansouri Taleghani B, Mueller BU, Novak U, Pabst T. Alva LC, et al. Among authors: mueller bu. Transfusion. 2018 Oct;58(10):2365-2373. doi: 10.1111/trf.14895. Epub 2018 Sep 10. Transfusion. 2018. PMID: 30203418

5

Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia.

Wetzel D, Mueller BU, Mansouri Taleghani B, Baerlocher GM, Seipel K, Leibundgut K, Pabst T. Wetzel D, et al. Among authors: mueller bu. Br J Haematol. 2015 Jan;168(2):268-73. doi: 10.1111/bjh.13118. Epub 2014 Sep 12. Br J Haematol. 2015. PMID: 25212255

6

Myelodysplastic syndromes and acute myeloid leukemias in the elderly.

Mueller BU, Seipel K, Pabst T. Mueller BU, et al. Eur J Intern Med. 2018 Dec;58:28-32. doi: 10.1016/j.ejim.2018.05.026. Eur J Intern Med. 2018. PMID: 30527920 Review.

7

The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.

Seipel K, Marques MAT, Sidler C, Mueller BU, Pabst T. Seipel K, et al. Among authors: mueller bu. Cancers (Basel). 2018 May 31;10(6):170. doi: 10.3390/cancers10060170. Cancers (Basel). 2018. PMID: 29857559 Free PMC article.

8

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin.

Seipel K, Marques MAT, Sidler C, Mueller BU, Pabst T. Seipel K, et al. Among authors: mueller bu. Haematologica. 2018 Nov;103(11):1862-1872. doi: 10.3324/haematol.2018.191650. Epub 2018 Jul 5. Haematologica. 2018. PMID: 29976747 Free PMC article.

9

ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.

Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG. Mueller BU, et al. Blood. 2006 Apr 15;107(8):3330-8. doi: 10.1182/blood-2005-07-3068. Epub 2005 Dec 13. Blood. 2006. PMID: 16352814 Free PMC article.

10

CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16).

Helbling D, Mueller BU, Timchenko NA, Schardt J, Eyer M, Betts DR, Jotterand M, Meyer-Monard S, Fey MF, Pabst T. Helbling D, et al. Among authors: mueller bu. Blood. 2005 Aug 15;106(4):1369-75. doi: 10.1182/blood-2004-11-4392. Epub 2005 Apr 26. Blood. 2005. PMID: 15855281

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results